ResultsIQ › Latest results › Vijaya Diagnostic Centre Limited
Vijaya Diagnostic Centre Limited Q2 FY27 results press release summary
NSE: VIJAYA · BSE: 543350
Results press release of 3 Nov 2026, summarised by AI from the filing.
Another 3 hubs and 7 spokes expected in H2 FY27, then 3 additional hubs in Q1 FY28.
Key takeaways
- Expansion guidance Another 3 hubs and 7 spokes expected in H2 FY27, then 3 additional hubs in Q1 FY28.
- North-East entry Business Transfer Agreement signed to acquire Arya Wellness Centre in Guwahati, Assam, marking entry into the North-East.
- Volume driver Revenue growth supported by 16.5% volume growth, with existing centres up approximately 20%.
- Forward-looking risk Forward-looking statements are subject to risks including economic environment changes, tax laws, import duties, litigation and labour relations.
Vijaya Diagnostic Centre Limited Q2 FY27 results
As filed: Revenue ₹255 cr (+26% year on year), EBITDA ₹113 cr (+38% year on year), PAT ₹59.5 cr (+38% year on year), EBITDA margin 44.2% (+355 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹231 cr (+23% year on year), EBITDA ₹98.5 cr (+35% year on year), PAT ₹53.1 cr (+36% year on year), EBITDA margin 42.7% (+383 bps). Score 80 of 100, Above trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 383 bps year on year. Revenue rose ₹43.0 cr on a year ago, more than the ₹32.0 cr it added the year before. Share price after the results: +9.0% in 29 days (Nifty 500: −2.0%).
- Q4 FY26: Revenue ₹219 cr (+27% year on year), EBITDA ₹95.5 cr (+40% year on year), PAT ₹47.9 cr (+37% year on year), EBITDA margin 43.5% (+423 bps). Score 88 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 423 bps year on year. Revenue rose ₹46.4 cr on a year ago, more than the ₹18.0 cr it added the year before. Share price after the results: +13.6% in 29 days (Nifty 500: −3.2%).
- Q3 FY26: Revenue ₹205 cr (+21% year on year), EBITDA ₹86.1 cr (+28% year on year), PAT ₹43.2 cr (+23% year on year), EBITDA margin 41.9% (+229 bps). Score 64 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were above it. EBITDA margin rose 229 bps year on year. Revenue rose ₹36.2 cr on a year ago, more than the ₹36.0 cr it added the year before. Share price after the results: −5.8% in 28 days (Nifty 500: −8.2%).
- Q2 FY26: Revenue ₹202 cr (+10% year on year), EBITDA ₹82.0 cr (+9% year on year), PAT ₹43.0 cr (+2% year on year), EBITDA margin 40.6% (−39 bps). Score 26 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 39 bps year on year. Revenue rose ₹19.0 cr on a year ago, against ₹44.0 cr the year before. Share price after the results: +5.3% in 30 days (Nifty 500: +0.3%).
- Q1 FY26: Revenue ₹188 cr (+21% year on year), EBITDA ₹73.0 cr (+20% year on year), PAT ₹39.0 cr (+22% year on year), EBITDA margin 38.8% (−27 bps). Score 49 of 100, In line with trend. Revenue and EBITDA growth were below the company's own trend; profit growth was in line with it. EBITDA margin fell 27 bps year on year. Revenue rose ₹32.0 cr on a year ago, against ₹35.0 cr the year before. Share price after the results: −11.6% in 29 days (Nifty 500: −0.3%).
- Q4 FY25: Revenue ₹173 cr (+12% year on year), EBITDA ₹68.0 cr (+8% year on year), PAT ₹35.0 cr (+3% year on year), EBITDA margin 39.3% (−134 bps). Score 23 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 134 bps year on year. Revenue rose ₹18.0 cr on a year ago, against ₹34.0 cr the year before. Share price after the results: −3.7% in 30 days (Nifty 500: +3.7%).
- Q3 FY25: Revenue ₹169 cr (+27% year on year), EBITDA ₹67.0 cr (+26% year on year), PAT ₹35.0 cr (+35% year on year), EBITDA margin 39.6% (−20 bps). Score 72 of 100, Above trend. EBITDA margin fell 20 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 8% from last quarter.
Past price moves after results do not indicate future moves. Not a recommendation.
Vijaya Diagnostic Centre Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Earnings call (4 Nov 2026), Results deck (3 Nov 2026), Results press release (3 Nov 2026)
- Q1 FY27: Earnings call (7 Aug 2026), Results deck (6 Aug 2026), Results press release (6 Aug 2026), Results press release (6 Aug 2026)
- Q4 FY26: Earnings call (8 May 2026), Results deck (7 May 2026)
- Q3 FY26: Earnings call (13 Feb 2026), Results deck (13 Feb 2026), Results press release (13 Feb 2026)
- Q2 FY26: Earnings call (4 Nov 2025), Results deck (4 Nov 2025), Results press release (4 Nov 2025)
- Q1 FY26: Earnings call (28 Jul 2025), Results deck (28 Jul 2025), Results press release (28 Jul 2025), Results press release (28 Jul 2025)
- Q4 FY25: Earnings call (12 May 2025), Results deck (12 May 2025)
- Other events: Strategy deck (11 Sep 2026)
Figures from the company's filings with NSE and BSE. Not investment advice.